AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
Net loss: US$162.9m (loss widened by 11% from FY 2023). US$0.55 loss per share (further deteriorated from US$0.51 loss in FY 2023). NasdaqGS:ABCL Earnings and Revenue Growth March 1st 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period AbCellera Biologics EPS Beats Expectations, Revenues Fall Short Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) exceeded analyst estimates by 6.6%. Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Performance of the American Life Sciences industry. The company's shares are down 15% from a week ago. Risk Analysis Before you tak
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025Business Wire
- AbCellera Biologics Inc. (NASDAQ: ABCL) had its "hold" rating re-affirmed by analysts at Benchmark Co..MarketBeat
- AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (NASDAQ: ABCL) had its price target lowered by analysts at Stifel Nicolaus from $12.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- AbCellera Reports Full Year 2024 Business ResultsBusiness Wire
ABCL
Earnings
- 11/4/24 - Miss
ABCL
Sec Filings
- 3/11/25 - Form 4
- 3/10/25 - Form 4
- 3/7/25 - Form 4
- ABCL's page on the SEC website